Zacks Investment Research·Sep 3, 2026
QURE Submits Application for Gene Therapy for Huntington's DiseaseQURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
uniQure's post-royalty-sale revenue base remains volatile and insufficient to offset a heavy R&D cost structure, with TTM revenue down 40.6% and quarterly operating losses consistently between -$39M and -$56M. The recent $413.0M cash balance (up from $80.2M) e...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | -$1.22-48.4% vs -$0.82 | $6M+7.2% vs $5M |
Q2 2026 May 5, 2026 | -$0.85+3.4% vs -$0.88 | $4M-31.6% vs $5M |
Q2 2026 Mar 2, 2026 | -$0.56+39.8% vs -$0.93 | $6M+4.5% vs $5M |
Q4 2025 Nov 10, 2025 | -$1.38-62.4% vs -$0.85 | $4M-23.6% vs $5M |
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
On Wednesday, uniQure N.V. (NASDAQ:QURE) submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington's disease.
Dutch gene therapy developer uniQure said on Wednesday it had applied for U.S. approval of its experimental treatment for Huntington's disease after the FDA reversed its earlier position on the drug, sending the company's shares up 5% in premarket trading.
Benchmark QURE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for uniQure N.V. (QURE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $45.28 | $3.14B | -13.09 | -40.64% | -1236% | -207.1% | — | |
| $20.81 | $2.2B | -2.92 | 15.58% | -6.93% | -9.96% | — | |
| $63.37 | $12.25B | 35.21 | 12.87% | 2.14% | 1.18% | — | |
| $59.03 | $5.69B | -9.12 | -89.97% | -3368.72% | -24.39% | — | |
| $2.92 | $448.11M | -1.62 | 25.39% | -157.32% | -196.63% | — | |
| $12.69 | $1.42B | -3.33 | 16.92% | -672.16% | -57.79% | — |
uniQure N.V. (QURE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
uniQure N.V. (QURE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jun 24, 2026·SEC
Jun 22, 2026·SEC
Get notified when QURE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
uniQure N.V. (QURE) stock FAQ — growth, dividends, profitability & financials explained
uniQure N.V. (QURE) reported $18.7M in revenue for fiscal year 2025.
uniQure N.V. (QURE) saw revenue decline by 40.6% over the past year.
uniQure N.V. (QURE) reported a net loss of $252.2M for fiscal year 2025.
uniQure N.V. (QURE) has a return on equity (ROE) of -207.1%. Negative ROE indicates the company is unprofitable.
uniQure N.V. (QURE) had negative free cash flow of $161.0M in fiscal year 2025, likely due to heavy capital investments.
